The stock has a 36-month beta value of 0.93. Opinions on the stock are mixed, with 5 analysts rating it as a “buy,” 1 as “overweight,” 1 as “hold,” and 0 as “sell.”
The public float for AVTX is 8.49M, and at present, short sellers hold a 1.36% of that float. On April 16, 2025, the average trading volume of AVTX was 71.70K shares.
AVTX) stock’s latest price update
Avalo Therapeutics Inc (NASDAQ: AVTX)’s stock price has gone decline by -8.92 in comparison to its previous close of 5.38, however, the company has experienced a -10.75% decrease in its stock price over the last five trading days. globenewswire.com reported 2025-03-26 that WAYNE, Pa. and ROCKVILLE, Md., March 26, 2025 (GLOBE NEWSWIRE) — Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical-stage biotechnology company dedicated to treating immune dysregulation, today announced the appointment of Michael Heffernan as Chairman of the Board of Directors (“Board”). Mr. Heffernan will succeed Dr. Garry Neil as Chairman of the Board. Dr. Neil will continue as a Board member and Chief Executive Officer (CEO) of the Company.
AVTX’s Market Performance
Avalo Therapeutics Inc (AVTX) has seen a -10.75% fall in stock performance for the week, with a -36.28% decline in the past month and a -24.85% plunge in the past quarter. The volatility ratio for the week is 18.19%, and the volatility levels for the past 30 days are at 14.02% for AVTX. The simple moving average for the past 20 days is -28.15% for AVTX’s stock, with a -47.71% simple moving average for the past 200 days.
Analysts’ Opinion of AVTX
Many brokerage firms have already submitted their reports for AVTX stocks, with Stifel repeating the rating for AVTX by listing it as a “Buy.” The predicted price for AVTX in the upcoming period, according to Stifel is $36 based on the research report published on March 25, 2025 of the current year 2025.
Jefferies, on the other hand, stated in their research note that they expect to see AVTX reach a price target of $23. The rating they have provided for AVTX stocks is “Buy” according to the report published on March 25th, 2025.
Piper Sandler gave a rating of “Overweight” to AVTX, setting the target price at $48 in the report published on February 28th of the current year.
AVTX Trading at -32.34% from the 50-Day Moving Average
After a stumble in the market that brought AVTX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -73.92% of loss for the given period.
Volatility was left at 14.02%, however, over the last 30 days, the volatility rate increased by 18.19%, as shares sank -36.94% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -38.90% lower at present.
During the last 5 trading sessions, AVTX fell by -10.75%, which changed the moving average for the period of 200-days by -62.88% in comparison to the 20-day moving average, which settled at $6.82. In addition, Avalo Therapeutics Inc saw -34.05% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at AVTX starting from Almenoff June Sherie, who purchase 500 shares at the price of $13.00 back on Nov 13 ’24. After this action, Almenoff June Sherie now owns 1,000 shares of Avalo Therapeutics Inc, valued at $6,500 using the latest closing price.
Almenoff June Sherie, the Director of Avalo Therapeutics Inc, purchase 500 shares at $12.50 during a trade that took place back on Nov 12 ’24, which means that Almenoff June Sherie is holding 500 shares at $6,250 based on the most recent closing price.
Stock Fundamentals for AVTX
Current profitability levels for the company are sitting at:
- -92.68 for the present operating margin
- 1.75 for the gross margin
The net margin for Avalo Therapeutics Inc stands at -79.66. The total capital return value is set at -0.28. Equity return is now at value -50.06, with -40.91 for asset returns.
Based on Avalo Therapeutics Inc (AVTX), the company’s capital structure generated 0.0 points at debt to capital in total, while cash flow to debt ratio is standing at -86.37. The debt to equity ratio resting at 0.0. The interest coverage ratio of the stock is -39.34.
Currently, EBITDA for the company is -68.51 million with net debt to EBITDA at 3.51. When we switch over and look at the enterprise to sales, we see a ratio of -185.23. The receivables turnover for the company is 0.72for trailing twelve months and the total asset turnover is 0.0. The liquidity ratio also appears to be rather interesting for investors as it stands at 19.96.
Conclusion
To sum up, Avalo Therapeutics Inc (AVTX) has seen a bad performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
